Dow Up0.51% Nasdaq Up0.24%

Nxstage Medical, Inc. (NXTM)

-NasdaqGS
17.34 Down 0.29(1.64%) Nov 21, 4:00PM EST
|After Hours : 17.34 Up 0.00 (0.01%) Nov 21, 4:45PM EST
ProfileGet Profile for:
Nxstage Medical, Inc.
350 Merrimack Street
Lawrence, MA 01843
United States - Map
Phone: 978-687-4700
Website: http://www.nxstage.com

Details 
Index Membership:N/A
Sector:Healthcare
Industry:Medical Appliances & Equipment
Full Time Employees:3,200

Business Summary 

NxStage Medical, Inc., a medical device company, develops, manufactures, and markets products for the treatment of kidney failure, fluid overload, and related blood treatments and procedures. Its primary product is the NxStage System One, a portable hemodialysis system used for the treatment of acute and chronic kidney failure, and fluid overload. The company operates in two segments, System One and In-Center. The System One segment sells and rents the NxStage System One and PureFlow SL dialysate preparation equipment. This segment also sells extracorporeal disposable products, which are primarily used for in-center dialysis treatments for patients with end-stage renal disease (ESRD) in the home and critical care markets. The In-Center segment sells blood tubing sets and needles for hemodialysis primarily for the treatment of ESRD patients at dialysis centers; and needles for apheresis. NxStage Medical, Inc. markets its products through direct sales force and distributors to hospitals and dialysis centers in the United States and internationally. The company, formerly known as QB Medical, Inc., was founded in 1998 and is headquartered in Lawrence, Massachusetts.

Key Statistics


Company Websites 
Home Page
Search Yahoo! for:
More on Nxstage Medical, Inc.

Corporate Governance 
Nxstage Medical, Inc.’s ISS Governance QuickScore as of Nov 1, 2014 is 5. The pillar scores are Audit: 1; Board: 4; Shareholder Rights: 4; Compensation: 7.
Brought to you by Institutional Shareholder Services (ISS)

Key Executives 
 PayExercised
Mr. Jeffrey H. Burbank , 52
Founder, Chief Exec. Officer and Director
449.00K436.00K
Mr. Joseph E. Turk Jr., 46
Pres
318.00K115.00K
Mr. Matthew W. Towse , 51
Chief Financial Officer, Sr. VP and Treasurer
141.00K0.00
Ms. Winifred L. Swan Esq., 50
Sr. VP, Gen. Counsel and Sec.
301.00K13.00K
Mr. Todd M. Snell , 43
Sr. VP of Quality Assurance, Regulatory & Clinical Affairs
360.00K0.00
Amounts are as of Dec 31, 2013 and compensation values are for the last fiscal year ending on that date. Pay is salary, bonuses, etc.Exercised is the value of options exercised during the fiscal year.
Currency in USD.
View Insiders